Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid profiling in active ulcerative colitis treated with tofacitinib or infliximab
NL-OMON55536Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tofacitinib and infliximab in autoimmune colitis (2 arms), sponsored by Erasmus MC. Started Apr 2021; status: active, not recruiting.
02
Drugs
tofacitinibinfliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON55536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55536.